Analyzing the Price-to-Earnings Ratio of Clearside Biomedical Inc (CLSD)

The 36-month beta value for CLSD is also noteworthy at 2.32. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for CLSD is 63.00M, and at present, short sellers hold a 0.54% of that float. The average trading volume of CLSD on April 03, 2024 was 351.48K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

CLSD) stock’s latest price update

Clearside Biomedical Inc (NASDAQ: CLSD) has experienced a decline in its stock price by -11.39 compared to its previous closing price of 1.58. However, the company has seen a fall of -19.08% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-13 that Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

CLSD’s Market Performance

Clearside Biomedical Inc (CLSD) has experienced a -19.08% fall in stock performance for the past week, with a 0.72% rise in the past month, and a 19.66% rise in the past quarter. The volatility ratio for the week is 15.18%, and the volatility levels for the past 30 days are at 14.27% for CLSD. The simple moving average for the past 20 days is -14.87% for CLSD’s stock, with a 22.74% simple moving average for the past 200 days.

Analysts’ Opinion of CLSD

Many brokerage firms have already submitted their reports for CLSD stocks, with Wedbush repeating the rating for CLSD by listing it as a “Outperform.” The predicted price for CLSD in the upcoming period, according to Wedbush is $9 based on the research report published on December 15, 2021 of the previous year 2021.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see CLSD reach a price target of $10. The rating they have provided for CLSD stocks is “Buy” according to the report published on July 29th, 2021.

ROTH Capital gave a rating of “Buy” to CLSD, setting the target price at $8 in the report published on May 13th of the previous year.

CLSD Trading at -3.33% from the 50-Day Moving Average

After a stumble in the market that brought CLSD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.96% of loss for the given period.

Volatility was left at 14.27%, however, over the last 30 days, the volatility rate increased by 15.18%, as shares surge +0.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.53% upper at present.

During the last 5 trading sessions, CLSD fell by -19.08%, which changed the moving average for the period of 200-days by +5.26% in comparison to the 20-day moving average, which settled at $1.6450. In addition, Clearside Biomedical Inc saw 19.66% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CLSD starting from Chong Ngai Hang Victor, who purchase 30,000 shares at the price of $1.60 back on Mar 20 ’24. After this action, Chong Ngai Hang Victor now owns 30,000 shares of Clearside Biomedical Inc, valued at $48,000 using the latest closing price.

WHITMORE BRADFORD T, the 10% Owner of Clearside Biomedical Inc, purchase 444,444 shares at $1.35 during a trade that took place back on Feb 07 ’24, which means that WHITMORE BRADFORD T is holding 4,495,034 shares at $599,999 based on the most recent closing price.

Stock Fundamentals for CLSD

Current profitability levels for the company are sitting at:

  • -3.02 for the present operating margin
  • 0.95 for the gross margin

The net margin for Clearside Biomedical Inc stands at -4.42. The total capital return value is set at -0.91. Equity return is now at value -1310.02, with -76.15 for asset returns.

Based on Clearside Biomedical Inc (CLSD), the company’s capital structure generated 1.6 points at debt to capital in total, while cash flow to debt ratio is standing at -0.43. The debt to equity ratio resting at -2.66. The interest coverage ratio of the stock is -6.04.

Currently, EBITDA for the company is -24.78 million with net debt to EBITDA at -0.59. When we switch over and look at the enterprise to sales, we see a ratio of 14.43. The receivables turnover for the company is 48.39for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.42.

Conclusion

In summary, Clearside Biomedical Inc (CLSD) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts